According to the survey, there has been no real change in the percentage of gynecologic oncologists who routinely provide chemotherapy services in their practice (79%) in the 2010 survey compared to 80% in 2005.Those in a group practice (82%) and multi-specialty practice/clinic (82%) are much more likely to administer chemotherapy in their practice than those in an individual practice (55%), the survey showed.
Although 51% of gynecologic oncologists earn revenue from chemotherapy in addition to the E&M code, an overwhelming number of gynecologic oncologists (97%) plan to continue administering chemotherapy in the coming year. The majority of gynecologic oncologists also agree to treat new Medicare and Medicaid chemotherapy patients.
"In revenues and reimbursements for chemotherapy, it's been going down the past 3 or 4 years, and will continue to do so, like all medical reimbursements have been," Orr says. "But these physicians are saying we're in it for the long haul, we will continue to deliver excellent care, in a comprehensive approach for women. It's absolutely the right thing to do."
"These people are really attuned into what they are doing and that they want to contribute to the subspecialty," Orr says of his fellow practitioners. "When you look at the response to the survey, the attendance at our meetings, there are these high percentages because people want to deliver state of the art care."
Orr says he's been in practice more than 28 years, and hasn't looked back. "If I was 22 years old, and God said to me, "What are you going to do with your life? I would do exactly the same thing.